



*Published by the  
N.J. Department of Human Services,  
Division of Medical Assistance & Health Services  
for the N.J. Department of Health  
Division of HIV, STD, and TB Services*

# Medicaid Alert

MA-2022-02

October 2022

**TO:** Physicians, Advanced Practice Nurses (APNs), Federally Qualified Health Centers (FQHCs), Independent Clinics – **For Action**  
Managed Care Organizations – **For Information Only**

**SUBJECT:** **New Billing Procedure for Cabenuva® Administration**

**EFFECTIVE:** Immediately

**BACKGROUND:** Medicaid Newsletter Volume 31, No. 25, dated November 2021, announced that the New Jersey AIDS Drug Distribution Program (ADDP), within the NJ Department of Health's Division of HIV, STD and TB Services (DHSTS), would provide coverage and reimbursement for the **administration of cabotegravir 200mg and rilpivirine 300mg injections**, as well as reimbursement for the Cabenuva® drug acquisition cost.

The procedure code and modifier combination detailed below is to be used only for the administration of Cabenuva® to ADDP recipients.

**ACTION:** Providers requesting reimbursement for Cabenuva® administration should submit claims reporting the **CPT procedure code 96372 with the "AG" modifier (96372 AG)**. ADDP reimbursement for Cabenuva® administration is \$7.43 for each monthly dose, consisting of cabotegravir 200mg and rilpivirine 300mg by injection.

Providers are still required to bill the cost of Cabenuva® administration to a beneficiary's primary health benefit plan first to ensure that ADDP is the payer of last resort.

If you have any questions concerning this Alert, please contact the Gainwell Technologies Provider Services Unit at 1-800-776-6334.

**RETAIN THIS ALERT FOR FUTURE REFERENCE**